Dr. Reddy’s enters U.S. consumer health market through Ducere Pharma deal

India flag

Dr. Reddy’s Laboratories ($RDY) has acquired a portfolio of 6 over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories as it looks to add a new string to its growing bow of offerings.

The Indian generic, pharma and manufacturing company has acquired six OTC brands from NJ-based Ducere Pharma, including Doan’s, Bufferin, Nupercainal Ointment, Cruex Nail Gel, Comtrex, and Myoflex.

“These legacy products enjoy strong brand equity built over several decades,” explained Alok Sonig, EVP and head of Dr. Reddy’s in the U.S. “We are extremely excited to be entering the branded consumer health arena through these brands and embarking upon the next avenue of growth for our OTC business in the US.”


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

According to Sonig, Dr. Reddy’s will build upon the sales and marketing efforts for these brands and continue to focus on their expansion into existing and new market channels.

“We think Dr. Reddy’s is well-positioned to continue the successful growth of these brands,” says Samuel Hines of Casla Capital Management. “We feel confident that our brand-loyal consumers will be well-served by the deal.”

The deal will help shift Dr. Reddy’s business more deeply and more diversely into the U.S. and builds upon its growing portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

- check out the release

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.